Abstract
Medical technologists at The Ohio State University Hospitals Clinical Laboratories participated in an aggressive program to inoculate personnel at high risk of exposure to hepatitis B virus. The immune status of the participants, determined prior to vaccination, included hepatitis B surface antigen, hepatitis B surface antibody, and hepatitis B core IgG antibody tests. Of the 200 technologists found to be negative for all markers, 43 received the vaccine for hepatitis B virus, through injection in the buttocks. Antibody status was determined one month and 12 months following the third dose. Thirty two of the 43 (74%) had detectable antibody at one month, but 18 of those 32 (40%) had no detectable antibody eleven months later. Eleven of 43 (26%) never seroconverted; 14 of 43 (33%) were still positive after 12 months.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
